Insider Trading Alert - MPWR, DVA And TWO Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Aug. 12, 2014, 62 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $100.00 to $8,936,360.00.

Highlighted Stocks Traded by Insiders:

Monolithic Power Systems (MPWR) - FREE Research Report

Rao Meera, who is Cfo at Monolithic Power Systems, sold 1,192 shares at $42.51 on Aug. 12, 2014. Following this transaction, the Cfo owned 40,317 shares meaning that the stake was reduced by 2.87% with the 1,192-share transaction.

The shares most recently traded at $43.64, up $1.13, or 2.59% since the insider transaction. Historical insider transactions for Monolithic Power Systems go as follows:

  • 4-Week # shares sold: 46,431
  • 12-Week # shares sold: 59,291
  • 24-Week # shares sold: 168,503

The average volume for Monolithic Power Systems has been 290,100 shares per day over the past 30 days. Monolithic Power Systems has a market cap of $1.6 billion and is part of the technology sector and electronics industry. Shares are up 24.87% year-to-date as of the close of trading on Tuesday.

Monolithic Power Systems, Inc., a fabless semiconductor company, designs, develops, and markets analog and mixed-signal semiconductors for storage and computing, consumer electronics, communications, and industrial/automotive markets. The stock currently has a dividend yield of 1.41%. The company has a P/E ratio of 55.2. Currently, there are 5 analysts who rate Monolithic Power Systems a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on MPWR - FREE

TheStreet Quant Ratings rates Monolithic Power Systems as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, growth in earnings per share, compelling growth in net income and solid stock price performance. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. Get the full Monolithic Power Systems Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

DaVita HealthCare Partners (DVA) - FREE Research Report

Jiganti Jeanine Marie, who is Chief Compliance Officer at DaVita HealthCare Partners, sold 2,500 shares at $72.14 on Aug. 12, 2014. Following this transaction, the Chief Compliance Officer owned 3,526 shares meaning that the stake was reduced by 41.49% with the 2,500-share transaction.

Historical insider transactions for DaVita HealthCare Partners go as follows:

  • 4-Week # shares sold: 303
  • 12-Week # shares sold: 303
  • 24-Week # shares sold: 52,773

The average volume for DaVita HealthCare Partners has been 888,200 shares per day over the past 30 days. DaVita HealthCare Partners has a market cap of $15.4 billion and is part of the health care sector and health services industry. Shares are up 13.68% year-to-date as of the close of trading on Tuesday.

DaVita HealthCare Partners Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease. It operates kidney dialysis centers and provides related lab services primarily in outpatient dialysis centers and in contracted hospitals. The company has a P/E ratio of 22.7. Currently, there are 8 analysts who rate DaVita HealthCare Partners a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on DVA - FREE

TheStreet Quant Ratings rates DaVita HealthCare Partners as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full DaVita HealthCare Partners Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Two Harbors Investment (TWO) - FREE Research Report

Kasnet Stephen G, who is Director at Two Harbors Investment, sold 5,237 shares at $10.38 on Aug. 12, 2014. Following this transaction, the Director owned 87,826 shares meaning that the stake was reduced by 5.63% with the 5,237-share transaction.

The shares most recently traded at $10.44, up $0.06, or 0.57% since the insider transaction. Historical insider transactions for Two Harbors Investment go as follows:

  • 4-Week # shares sold: 53,165
  • 12-Week # shares sold: 53,165
  • 24-Week # shares bought: 15,000
  • 24-Week # shares sold: 53,165

The average volume for Two Harbors Investment has been 3.0 million shares per day over the past 30 days. Two Harbors Investment has a market cap of $3.8 billion and is part of the financial sector and real estate industry. Shares are up 12.39% year-to-date as of the close of trading on Tuesday.

Two Harbors Investment Corp. operates as a real estate investment trust (REIT) that focuses on investing in, financing, and managing residential mortgage-backed securities (RMBS), residential mortgage loans, mortgage servicing rights, and other financial assets. The stock currently has a dividend yield of 9.94%. The company has a P/E ratio of 104.6. Currently, there are 11 analysts who rate Two Harbors Investment a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on TWO - FREE

TheStreet Quant Ratings rates Two Harbors Investment as a hold. The company's strengths can be seen in multiple areas, such as its attractive valuation levels, increase in stock price during the past year and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and feeble growth in the company's earnings per share. Get the full Two Harbors Investment Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists

Purdue Pharma Unloads Sales Staff, Transitioning From Painkiller Focus

Purdue Pharma Unloads Sales Staff, Transitioning From Painkiller Focus

Dow Finishes Lower as Nasdaq Posts New Record

Dow Finishes Lower as Nasdaq Posts New Record

Airlines Rebuke Trump Policy of Separating Children

Airlines Rebuke Trump Policy of Separating Children

Deutsche Bank Fined $205 Million Over Currency-Trading Violations

Deutsche Bank Fined $205 Million Over Currency-Trading Violations